Validation of a claims-based antipsychotic polypharmacy measure

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 6, 2014, Pages 628-635

  Leckman Westin, Emily ^a,b   Kealey, Edith ^a   Gupta, Nitin ^a   Chen, Qingxian ^a   Gerhard, Tobias ^e   Crystal, Stephen ^e   Olfson, Mark ^d   Finnerty, Molly ^a,c  

^a NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

^b UNIVERSITY AT ALBANY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Administrative data; Antipsychotic polypharmacy; Medicaid; Pharmacoepidemiology; Positive predictive value; Sensitivity

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CHILD; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAID; MEDICAL RECORD REVIEW; MENTAL HEALTH CENTER; POLYPHARMACY; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG UTILIZATION; INSURANCE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARDS; UNITED STATES; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; DRUG UTILIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; POLYPHARMACY; UNITED STATES; YOUNG ADULT;

EID: 84901847678     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3609     Document Type: Article

References (38)

1. Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J 2010; 46(6): 523-530. DOI: 10.1007/s10597-009-9288-2
2. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 2010; 32(5): 949-959. DOI: 10.1016/j.clinthera.2010.04.021
3. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58(7): 1007-1010. DOI: 10.1176/appi.ps.58.7.1007
4. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther 2007; 29(1): 183-195. DOI: 10.1016/j.clinthera.2007.01.002
5. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1): 18-28. DOI: 10.1016/j.schres.2012.03.018
6. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35(2): 443-457. DOI: 10.1093/schbul/sbn018
7. Goff DC, Freudenreich O. Focus on polypharmacy in schizophrenia: does anyone truly benefit? Int J Neuropsychopharmacol 2004; 7(2): 109-111. DOI: 10.1017/S1461145704004183
8. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 2008; 31(1): 7-20, http://www.ncbi.nlm.nih.gov/pubmed/18095743
9. Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 2012; 35(3): 661-681. DOI: 10.1016/j.psc.2012.06.007
10. Megna JL, Kunwar AR, Mahlotra K, et al. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 2007; 13(2): 129-137. DOI: 10.1097/01.pra.0000265773.03756.3e
11. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11(3): 313-327, http://www.ncbi.nlm.nih.gov/pubmed/14965234
12. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010; 23(2): 103-111. DOI: 10.1097/YCO.0b013e3283366427
13. Centorrino F, Ventriglio A, Vincenti A, et al. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol 2010; 25(2): 179-186. DOI: 10.1002/hup.1095
14. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89(1-3): 91-100. DOI: 10.1016/j.schres.2006.08.017
15. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011; 11: 118. DOI: 10.1186/1471-244X-11-118
16. Centorrino F, Masters GA, Talamo A, et al. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 2012; 27(5): 521-526. DOI: 10.1002/hup.2257
17. Baandrup L, Sorensen J, Lublin H, et al. Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 2012; 13(3): 355-363. DOI: 10.1007/s10198-011-0308-0
18. Rupnow MF, Greenspan A, Gharabawi GM, et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 2007; 23(11): 2815-2822. DOI: 10.1185/030079907X233359
19. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006; 57(1): 127-129. DOI: 10.1176/appi.ps.57.1.127
20. Valuck RJ, Morrato EH, Dodd S, et al. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Curr Med Res Opin 2007; 23(10): 2567-2576. DOI: 10.1185/030079907X233214
21. Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008; 8: 19. DOI: 10.1186/1471-244X-8-19
22. Windfuhr K, Turnbull P, While D, et al. The incidence and associated risk factors for sudden unexplained death in psychiatric in-patients in England and Wales. J Psychopharmacol 2011; 25(11): 1533-1542. DOI: 10.1177/0269881110379288
23. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168(7): 702-708. DOI: 10.1176/appi.ajp.2011.10060908
24. Goren JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008; 34(10): 571-582, http://www.ncbi.nlm.nih.gov/pubmed/18947117
25. Medicaid Medical Directors Learning Network and Rutgers Center for Education and Research on Mental Health Therapeutics. Antipsychotic medication use in Medicaid children and adolescents: report and resource guide from a 16-state study. MMDLN/Rutgers CERTs Publication #1. July 2010. Distributed by Rutgers CERTs at http://rci.rutgers.edu/~cseap/MMDLNAPKIDS.html.
26. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26. DOI: 10.1186/1471-244X-5-26
27. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-1223. DOI: 10.1056/NEJMoa051688
28. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004; 65(10): 1377-1388, http://www.ncbi.nlm.nih.gov/pubmed/15491242
29. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007; 58(4): 489-495. DOI: 10.1176/appi.ps.58.4.489
30. Uttaro T, Finnerty M, White T, et al. Reduction of concurrent antipsychotic prescribing practices through the use of PSYCKES. Adm Policy Ment Health 2007; 34(1): 57-61. DOI: 10.1007/s10488-006-0075-x
31. Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 2006; 84(1): 90-99. DOI: 10.1016/j.schres.2006.02.023
32. Essock, SM, Covell, NH, Leckman-Westin, E, et al. Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatr Serv 2009; 60(12): 1595-1602.
33. Shireman TI, Svarstad BL, Sweeney JK. Validity of claims data for long-acting injectable medications. J Pharmacoepidemiol 1999; 7(2): 41-55
34. Bergstralh E. Calculate exact binomial confidence intervals. Revised 2008. Available at http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros
35. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000; 34: 200-207.
36. Lambert TJ: Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007; 68(suppl 6): 10-13.
37. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008; 69(suppl 1): 4-17.
38. PSYCKES Medicaid online resources. https://www.omh.ny.gov/omhweb/psyckes_medicaid/